Gedatolisib plus fulvestrant (Faslodex) with or without palbociclib (Ibrance) continued to showcase significant efficacy vs fulvestrant alone when used as second-line treatment in patients with hormone receptor–positive, HER2-negative, PIK3CA…
Gedatolisib Plus Fulvestrant ± Palbociclib Is a Potential New SOC in HR+ PIK3CA Wild-Type Advanced Breast Cancer
